Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
May 19 2021 - 7:30AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company
focused on developing novel therapeutics for the treatment of
cancer and viral diseases, today announced the appointment of Tariq
Arshad, MD, MBA to the newly-created position of Senior Vice
President, Chief Medical Officer. Dr. Arshad brings more than 20
years of biotech and pharmaceutical experience to Qualigen
Therapeutics during a dynamic time of growth and implementation of
long-range strategy.
“We are delighted to welcome Tariq to Qualigen
as our Chief Medical Officer during this exciting time where he
will serve in a mission-critical role as we advance our oncology
and viral disease pipeline programs,” stated Michael Poirier,
Chairman and Chief Executive Officer at Qualigen Therapeutics.
Dr. Arshad is an oncologist with expertise in
both early and late stage clinical development at several leading
and emergent biopharmaceutical companies, including leadership
roles at Becton Dickinson, Sanofi Genzyme, Humanigen, XOMA, Merck,
Genentech, and Pfizer. Most recently, Dr. Arshad was Global
Head of Medical Affairs and Clinical Research for Becton Dickinson
BioSciences in San Jose, California where he led a team of MDs and
PhDs driving scientific strategy for a cutting-edge immuno-oncology
focused portfolio.
Dr. Arshad commented, “I am thrilled to join a
dedicated team with a calling to develop therapeutics for patients
with few treatment options. I plan to apply my expertise in
immuno-oncology and clinical development to help solve the medical
problems that devastate patients who suffer from these
conditions.”
About Qualigen Therapeutics,
Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing novel therapeutics for the treatment
of cancer and infectious diseases, as well as maintaining and
expanding its core FDA-approved FastPack® System, which has been
used successfully in diagnostics for 20 years. Our cancer
therapeutics pipeline includes QN-247 (formerly referred to as ALAN
or AS1411-GNP), RAS-F and STARS™. QN-247 is a DNA coated gold
nanoparticle cancer drug candidate that has the potential to target
various types of cancer with minimal side effects; the nanoparticle
coating technology is similar to the core nanoparticle coating
technology used in our blood-testing diagnostic products. The
foundational aptamer of QN-247, QN-165 (formerly referred to as
AS1411), is also a drug candidate for treating COVID-19 and other
viral-based infectious diseases; we currently plan that our first
clinical trial would be a trial of QN-165 against COVID-19. RAS-F
is a family of RAS oncogene protein-protein interaction inhibitor
small molecules for preventing mutated RAS genes' proteins from
binding to their effector proteins; preventing this binding could
stop tumor growth, especially in pancreatic, colorectal and lung
cancers. STARS is a DNA/RNA-based treatment device candidate for
removal from circulating blood of precisely targeted tumor-produced
and viral compounds.
Because Qualigen's therapeutic candidates are
still in the development stage, Qualigen's only products that are
currently commercially available are FastPack System diagnostic
instruments and test kits, used in physician offices, clinics and
small hospitals around the world. The FastPack System menu includes
rapid point-of-care diagnostic tests for cancer, men's health,
hormone function, and vitamin D status. Qualigen's facility in
Carlsbad, California is FDA and ISO Certified and its FastPack
product line is sold worldwide by its commercial partner Sekisui
Diagnostics, LLC.
For more information on Qualigen Therapeutics,
Inc., please visit https://www.qualigeninc.com.
Forward-Looking Statements
This news release contains forward-looking
statements by the Company that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for the development of therapeutic drug candidates.
Actual events or results may differ from the Company's
expectations. For example, there can be no assurance that clinical
trials will be approved to begin by or will proceed as contemplated
by any projected timeline; that the Company will successfully
develop any drugs or therapeutic devices; that preclinical or
clinical development of the Company's drugs or therapeutic devices
will be successful; that future clinical trial data will be
favorable or that such trials will confirm any improvements over
other products or lack negative impacts; that any drugs or
therapeutic devices will receive required regulatory approvals or
that they will be commercially successful; that patents will issue
on the Company's owned and in-licensed patent applications; that
such patents, if any, and the Company's current owned and
in-licensed patents would prevent competition; that the Company
will be able to procure or earn sufficient working capital to
complete the development, testing and launch of the Company's
prospective therapeutic products; or that the Company will be able
to maintain or expand market demand and/or market share for the
Company's diagnostic products. The Company's stock price could be
harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business (including events beyond the Company's control,
such as epidemics and resulting changes) can be found in the
Company's prior filings with the Securities and Exchange
Commission, available at www.sec.gov. The Company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this news release, except as required by law.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor Relations:
For further information: David KugelmanAtlanta
Capital Partners, LLC (404) 856-9157 Office(866) 692-6847 Toll Free
- U.S. & Canadadk@atlcp.com
Tony SchorInvestor Awareness, Inc. (847)
971-0922tony@investorawareness.com
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Sep 2023 to Sep 2024